IP Library › Assignment 042177/0032
Patent Assignment
Reel/Frame 042177/0032

Assignment of Assignor's Interest

Recorded: 2017-04-06 Pages: 49
Assignor
Assignee
RANA THERAPEUTICS, INC.
128 SPRING STREET, LEXINGTON, MASSACHUSETTS, 02421
Covered Properties (112)
Delivery of Mrna for the Augmentation of Proteins and Enzymes in Human Genetic Diseases
Mrna for Use in Treatment of Human Genetic Diseases
Cleavable Lipids
Compositions and Methods for Mrna Delivery
Ionizable Cationic Lipids
Lipid-Derived Neutral Nanoparticles
Nuclease Resistant Polynucleotides and Uses Thereof
Pulmonary Delivery of Mrna to Non-Lung Target Cells
Compositions and Methods for Mrna Delivery
Ribonucleic Acids with 4'-Thio-Modified Nucleotides and Related Methods
Quantitative Assessment for Cap Efficiency of Messenger Rna
Quantitative Assessment for Cap Efficiency of Messenger Rna
Methods and Compositions for Delivering Mrna Coded Antibodies
Mrna Therapeutic Compositions and Use to Treat Diseases and Disorders
Methods for Purification of Messenger Rna
Synergistic Enhancement of the Delivery of Nucleic Acids via Blended Formulations
Cftr Mrna Compositions and Related Methods and Uses
Messenger Rna Based Viral Production
Cns Delivery of Mrna and Uses Thereof
Lipid Formulations for Delivery of Messenger Rna
Mrna Therapy for Phenylketonuria
Mrna Therapy for Argininosuccinate Synthetase Deficiency
Mrna Therapy for the Treatment of Ocular Diseases
Methods for Purification of Messenger Rna
Biodegradable Lipids for Delivery of Nucleic Acids
Stereochemically Enriched Compositions for Delivery of Nucleic Acids
Encapsulation of Messenger Rna
Messenger Rna Therapy for Treatment of Articular Disease
Mrna Therapy for Pompe Disease
Modification of Rna-Related Enzymes for Enhanced Production
Delivery of Mrna for the Augmentation of Proteins and Enzymes in Human Genetic Diseases
Application: 12/957,340 →
Publication: US 2011/0244026
Mrna for Use in Treatment of Human Genetic Diseases
Patent: 8,853,377 →
Application: 13/306,781 →
Publication: US 2012/0142756
Liver Specific Delivery of Messenger Rna
Application: 13/800,501 →
Publication: US 2013/0195967
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
Application: 14/124,608 →
Publication: US 2014/0206753
Cleavable Lipids
Patent: 9,717,690 →
Application: 14/124,615 →
Publication: US 2014/0288160
Cftr Mrna Compositions and Related Methods and Uses
Patent: 9,181,321 →
Application: 14/307,322 →
Publication: US 2015/0038556
Mrna Therapy for Fabry Disease
Patent: 9,308,281 →
Application: 14/308,546 →
Publication: US 2014/0294938
Pulmonary Delivery of Mrna
Patent: 9,597,413 →
Application: 14/308,554 →
Publication: US 2014/0294939
Mrna Therapy for Urea Cycle Disorders
Application: 14/309,387 →
Publication: US 2014/0294940
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
Patent: 9,061,021 →
Application: 14/325,594 →
Publication: US 2015/0004217
Ionizable Cationic Lipids
Patent: 9,546,128 →
Application: 14/389,023 →
Publication: US 2015/0166462
Lipid-Derived Neutral Nanoparticles
Patent: 9,877,919 →
Application: 14/389,165 →
Publication: US 2015/0086613
Nuclease Resistant Polynucleotides and Uses Thereof
Application: 14/406,424 →
Publication: US 2015/0267192
Pulmonary Delivery of Mrna to Non-Lung Target Cells
Application: 14/406,504 →
Publication: US 2015/0157565
Lipid Formulations for Delivery of Messenger Rna
Patent: 9,629,804 →
Application: 14/521,161 →
Publication: US 2015/0140070
Cns Delivery of Mrna and Uses Thereof
Application: 14/521,168 →
Publication: US 2015/0110857
Mrna Therapy for Phenylketonuria
Patent: 9,522,176 →
Application: 14/521,323 →
Publication: US 2015/0110858
Mrna Therapy for Argininosuccinate Synthetase Deficiency
Application: 14/521,351 →
Publication: US 2015/0110859
COMPOSITIONS AND METHODS FOR mRNA DELIVERY
Application: 14/650,104 →
Publication: US 2015/0366997
Methods for Purification of Messenger Rna
Patent: 9,850,269 →
Application: 14/696,140 →
Publication: US 2015/0376220
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
Patent: 9,956,271 →
Application: 14/714,871 →
Publication: US 2016/0101160
Stereochemically Enriched Compositions for Delivery of Nucleic Acids
Application: 14/749,027 →
Publication: US 2015/0376144
Mrna Therapeutic Compositions and Use to Treat Diseases and Disorders
Application: 14/774,263 →
Publication: US 2016/0184458
Synergistic Enhancement of the Delivery of Nucleic Acids via Blended Formulations
Application: 14/775,818 →
Publication: US 2016/0151409
Methods and Compositions for Delivering Mrna Coded Antibodies
Application: 14/775,835 →
Publication: US 2016/0031981
Quantitative Assessment for Cap Efficiency of Messenger Rna
Application: 14/775,844 →
Publication: US 2016/0002705
Quantitative Assessment for Cap Efficiency of Messenger Rna
Patent: 9,970,047 →
Application: 14/775,846 →
Publication: US 2016/0032356
Methods for Purification of Messenger Rna
Patent: 9,957,499 →
Application: 14/775,915 →
Publication: US 2016/0040154
Ribonucleic Acids with 4'-Thio-Modified Nucleotides and Related Methods
Application: 14/776,506 →
Publication: US 2016/0031928
Encapsulation of Messenger Rna
Patent: 9,668,980 →
Application: 14/790,562 →
Publication: US 2016/0038432
Cftr Mrna Compositions and Related Methods and Uses
Patent: 9,713,626 →
Application: 14/876,071 →
Publication: US 2016/0106772
Messenger Rna Based Viral Production
Application: 14/898,071 →
Publication: US 2016/0122727
Messenger Rna Therapy for Treatment of Articular Disease
Patent: 9,943,595 →
Application: 14/959,453 →
Publication: US 2016/0158354
Mrna Therapy for Pompe Disease
Application: 15/073,163 →
Publication: US 2016/0324940
Liver Specific Delivery of Messenger Rna
Application: 15/092,226 →
Publication: US 2016/0287725
Mrna Therapy for the Treatment of Ocular Diseases
Application: 15/128,303 →
Publication: US 2017/0143848
Modification of Rna-Related Enzymes for Enhanced Production
Application: 15/294,249 →
Publication: US 2017/0159093
Biodegradable Lipids for Delivery of Nucleic Acids
Application: 15/314,818 →
Publication: US 2017/0246319
Mrna Therapy for Phenylketonuria
Application: 15/349,720 →
Publication: US 2017/0073648
Ionizable Cationic Lipids
Application: 15/368,280 →
Publication: US 2017/0240501
Delivery of Mrna for the Augmentation of Proteins and Enzymes in Human Genetic Diseases
Application: 61/265,653 →
Mrna for Use in Treatment of Human Genetic Diseases
Application: 61/418,389 →
Cleavable Lipids
Application: 61/494,745 →
Compositions and Methods for Mrna Delivery
Application: 61/494,881 →
Lyophilized Liposomal Formulations
Application: 61/494,882 →
Ionizable Cationic Lipids
Application: 61/617,468 →
Modified Drug Encapsulated Liposomal Compositions and Related Methods of Use
Application: 61/617,478 →
Pulmonary Delivery of mRNA to Non-Lung Target Cells
Application: 61/657,452 →
Nuclease Resistant Polynucleotides and Related Methods
Application: 61/657,465 →
Compositions and Methods for Mrna Delivery
Application: 61/734,753 →
Cftr Mrna Compositions and Related Methods and Uses
Application: 61/783,663 →
Quantitative Assessment for Cap Efficiency of Messenger Rna
Application: 61/784,253 →
Quantitative Assessment for Cap Efficiency of Messenger Rna
Application: 61/784,337 →
Mrna Therapeutic Compositions and Use to Treat Diseases and Disorders
Application: 61/784,766 →
Methods and Compositions for Delivering Mrna Coded Antibodies
Application: 61/784,903 →
Methods for Purification of Messenger Rna
Application: 61/784,996 →
Ribonucleic Acids with 4'-Thio-Modified Nucleotides and Related Methods
Application: 61/785,098 →
Synergistic Enhancement of the Delivery of Nucleic Acids via Blended Formulations
Application: 61/789,375 →
Messenger Rna Based Viral Production
Application: 61/834,512 →
Cns Delivery of Mrna and Uses Thereof
Application: 61/894,246 →
Mrna Therapy for Argininosuccinate Synthetase Deficiency
Application: 61/894,294 →
Lipid Formulations for Delivery of Messenger Rna
Application: 61/894,299 →
Mrna Therapy for Phenylketonuria
Application: 61/894,303 →
Methods and Compositions for Delivering Mrna Coded Antibodies
Application: 61/920,165 →
Lipid Formulations for Delivery of Messenger Rna
Application: 61/953,516 →
Messenger RNA Therapy for the Treatement of Ocular Diseases
Application: 61/969,483 →
Methods for Purification of Messenger Rna
Application: 61/984,503 →
Biodegradable Lipids for Delivery of Nucleic Acids
Application: 62/005,266 →
Stereochemically Enriched Compositions for Delivery of Nucleic Acids
Application: 62/016,512 →
Cns Delivery of Mrna and Uses Thereof
Application: 62/020,161 →
Encapsulation of Messenger Rna
Application: 62/020,163 →
Mrna Therapy for Treatment of Articular Disease
Application: 62/088,141 →
Mrna Therapy for Pompe Disease
Application: 62/135,338 →
Modification of Rna-Related Enzymes for Enhanced Production
Application: 62/241,350 →
Multimeric Coding Nucleic Acid and Uses Thereof
Application: 62/320,073 →
Messenger RNA Therapy for the Treatment of Ornithine Transcarbamylase Deficiency
Application: 62/349,331 →
Novel Lipid Nanoparticle Formulations of Mrna
Application: 62/420,413 →
Novel Ice-Based Lipid Nanoparticle Formulation for Delivery of Mrna
Application: 62/420,421 →
Novel Ice-Based Lipid Nanoparticle Formulation for Delivery of Mrna
Application: 62/420,428 →
Novel Formulations for Subcutaneous Delivery of Nucleic Acids
Application: 62/420,435 →
Novel Ice-Based Lipid Nanoparticle Formulation for Delivery of Mrna
Application: 62/421,007 →
Novel Ice-Based Lipid Nanoparticle Formulation for Delivery of Mrna
Application: 62/421,021 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Feb 28, 2011
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES
Reel/Frame 025873/0592 →
Assignment of Assignor's Interest Mar 16, 2011
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES
Reel/Frame 025966/0743 →
Assignment of Assignor's Interest May 31, 2012
From: CONCINO, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES
Reel/Frame 028295/0718 →
Assignment of Assignor's Interest Sep 3, 2013
From: HEARTLEIN, MICHAEL; GUILD, BRAYDON CHARLES; DEROSA, FRANK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 031157/0930 →
Assignment of Assignor's Interest Oct 3, 2013
From: RUDOLPH, CARSTEN; PLANK, CHRISTIAN
To: ETHRIS GMBH
Reel/Frame 031339/0001 →
Assignment of Assignor's Interest Oct 3, 2013
From: HEARTLEIN, MICHAEL; GUILD, BRAYDON CHARLES; DEROSA, FRANK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 031338/0921 →
Assignment of Assignor's Interest Feb 14, 2014
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 032220/0179 →
Assignment of Assignor's Interest Feb 14, 2014
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 032220/0341 →
Assignment of Assignor's Interest Mar 28, 2014
From: GUILD, BRAYDON CHARLES; HEARTLEIN, MICHAEL; DEROSA, FRANK; ZHANG, JERRY CHI
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 032551/0705 →
Assignment of Assignor's Interest Jul 22, 2014
From: HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033368/0016 →
Assignment of Assignor's Interest Jul 22, 2014
From: DEROSA, FRANK; SMITH, LIANNE; HEARTLEIN, MICHAEL; GUILD, BRAYDON CHARLES
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033367/0862 →
Assignment of Assignor's Interest Aug 13, 2014
From: HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033521/0664 →
Assignment of Assignor's Interest Aug 14, 2014
From: HEARTLEIN, MICHAEL; GUILD, BRAYDON CHARLES; DEROSA, FRANK; SMITH, LIANNE
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033534/0676 →
Assignment of Assignor's Interest Aug 14, 2014
From: RUDOLPH, CARSTEN; PLANK, CHRISTIAN
To: ETHRIS GMBH
Reel/Frame 033534/0692 →
Assignment of Assignor's Interest Sep 18, 2014
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033768/0260 →
Assignment of Assignor's Interest Sep 18, 2014
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033773/0920 →
Assignment of Assignor's Interest Apr 8, 2015
From: HEARTLEIN, MICHAEL; DEROSA, FRANK; DIAS, ANUSHA
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035356/0533 →
Assignment of Assignor's Interest Apr 21, 2015
From: ANDERSON, DANIEL; DONG, YIZHOU
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 035454/0912 →
Assignment of Assignor's Interest Apr 21, 2015
From: HEARTLEIN, MICHAEL; DEROSA, FRANK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035454/0892 →
Assignment of Assignor's Interest Jun 4, 2015
From: DEROSA, FRANK; DIAS, ANUSHA; KARVE, SHRIRANG; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035788/0371 →
Assignment of Assignor's Interest Jun 5, 2015
From: CALIAS, PERICLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 035835/0210 →
Assignment of Assignor's Interest Sep 22, 2015
From: DEROSA, FRANK; KARVE, SHRIRANG; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 036621/0322 →
Assignment of Assignor's Interest Sep 30, 2015
From: DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 036695/0206 →
Assignment of Assignor's Interest Nov 12, 2015
From: DEROSA, FRANK; KARVE, SHRIRANG; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 037023/0327 →
Assignment of Assignor's Interest Nov 16, 2015
From: HEARTLEIN, MICHAEL; DEROSA, FRANK; DIAS, ANUSHA; KARVE, SHRIRANG
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 037050/0829 →